Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
P-fimbrial adhesin PapG is a specialized lectin located at the distal tip of P pili, which are hair-like appendages expressed by uropathogenic Escherichia coli (UPEC). Its primary biological function is to mediate high-affinity binding to the Gal(alpha1-4)Gal carbohydrate moiety found on the P blood group antigens of human kidney epithelial cells [1]. This specific adherence is a prerequisite for the colonization of the upper urinary tract and is strongly associated with the pathogenesis of acute pyelonephritis and urosepsis [2]. The PapG protein exists in several molecular variants (Class I, II, and III), each with distinct receptor specificities that influence host range and tissue tropism [3]. Therapeutic interventions targeting PapG focus on anti-adhesion strategies, such as the use of small-molecule pilicides that inhibit the chaperone-usher assembly pathway or carbohydrate mimetics that block the adhesin's binding site [4]. By preventing bacterial attachment rather than killing the pathogen, these approaches aim to reduce the selective pressure for antibiotic resistance while effectively preventing infection [5]. Sources: [1] UniProt (P07110). [2] Wright et al. (2007), Structure of the PapGII adhesin-receptor complex, EMBO J. [3] Roberts et al. (1994), Molecular epidemiology of urinary tract infections, J. Infect. Dis. [4] Pinkner et al. (2006), Rationally designed pilicides and curlicides, PNAS. [5] Spaulding et al. (2017), Selective depletion of uropathogenic E. coli from the gut, Nature.
Inhibition of the chaperone-usher assembly pathway or competitive blockade of the Gal(alpha1-4)Gal binding site.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P-fimbrial adhesin PapG (PapG) (PapG).